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Abstract 
NZ2114 is a promising candidate for therapeutic application owing to potent activity to gram-positive bacterium 
such as Streptococcus pneumoniae and Staphylococcus aureus. This work is the first report to describe the in vitro and 
in vivo antibacterial characteristics of NZ2114 against Streptococcus suis. It exhibited strong antimicrobial activity 
against S. suis type 2 strains CVCC 606, CVCC 3309, and CVCC 3928 at a low minimal inhibitory concentration (MIC) of 
0.03–0.06 μM. The NZ2114 killed over 99.9% of tested S. suis CVCC 606 in Mueller–Hinton medium within 4 h when 
treated with 4 × MIC. It caused only less than 0.25% hemolytic activity in the concentration of 256 μg/ml. Additionally, 
NZ2114 exhibited potent in vivo activity to S. suis. All mice were survival when the dosage was low to 0.2 mg/kg. Over 
99% of S. suis cells were killed within 4 h in blood, lung, liver and spleen with dosage of 10, 20, and 40 mg/kg in mice 
peritonitis models and no pathogen were detected after 24 h of treatment. Further, no pathological phenomenon 
in lung and low level of inflammatory cytokines in blood were detected. These results indicate that NZ2114 has the 
potential to be a new antimicrobial agent candidate for the clinical treatment of infection caused by S. suis type 2.
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Introduction
Streptococcus suis is an important pathogen associated 
with wide range of diseases in swine and human, includ-
ing septicemia, pneumonia, endocarditis, meningitis, and 
arthritis (Lun et  al. 2007). It was found that S. suis was 
the fourth most significant pathogen in the breeder and 
weaner site. S. suis can be transmitted to human beings 
by direct contact. The repeated intensive outbreaks of 
human S. suis infection have raised great public concern 
worldwide regarding S. suis as an emerging zoonotic 
pathogen. It is the most common cause of adult infection 
in Vietnam (Mai et al. 2008) and the second most com-
mon in Thailand (Suankratay et al. 2004). In Europe, the 
largest number of zoonotic infections due to S. suis, have 
been recorded in the Netherlands [Figure 1 in (Wertheim 
et al. 2009)]. In July, 2005, the largest outbreak of human 
S. suis infection occurred in Sichuan province, China, 
where 204 people were infected and 38 of them died 
(Normile 2005). There are 35 serotypes described and the 
composition of the capsule defines the serotype (types 
1–34 and 1/2). Serotype 2 is commonly associated with 
diseases in pigs and human beings, and is the most fre-
quently reported serotype worldwide (Costa et al. 2005). 
It has always been considered the most virulent serotype 
(Higgins and Gottschalk 2000).
S. suis type 2 is resistant to various environmental con-
ditions. It can survive for 10 min at 60  °C, 2 h at 50  °C, 
and 6  weeks in carcasses at 10  °C (Clifton-Hadley and 
Enright 1984). The penicillin G, accompanied by one or 
more other antibiotics including ceftriaxone, gentamicin, 
chloramphenicol, and ampicillin is the normal strat-
egy for S. suis infection treatment (Halaby et  al. 2000). 
However, with wide and over use of antibiotics, S. suis is 
resistant to many conventional drugs. More than 87% of 
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S. suis isolates are   resistant to oxytetracycline, erythro-
mycin, tylosin tartrate, and clindamycin in Spain (Vela 
et al. 2005). In addition, high levels of tetracycline resist-
ance (upto 90%) have also been reported from diseased 
and clinically healthy persons (Hoa et  al. 2011; Strang-
mann et al. 2002). Integrative conjugative elements (ICE) 
seem to play a key role in the transmission of resistance 
determinants, as demonstrated by genomic studies. 
Although S. suis is uniformly sensitive to penicillin or 
ampicillin, and low levels of resistance are reported (Var-
ela et al. 2013), there will be rare candidates when resist-
ance arise. In the other side, vaccines are the common 
strategy for the prevention of S. suis infection. Although 
various of vaccines are developed, the commonly used 
vaccines in pig industry, however, remain the inactivated 
autogenous vaccine generated from virulent strains iso-
lated from sick pigs (Haesebrouck et  al. 2004). One of 
the disadvantages of autogenous vaccines is the absence 
of safety and efficacy data. At present, there is no S. suis 
vaccine for human beings (Lun et  al. 2007). To prevent 
and treat infections caused by S. suis, novel and effective 
antimicrobial agents are needed.
Plectasin is a fungal defensin from Pseudoplectania 
nigrella and is active against Gram-positive bacteria such 
as Staphylococcus aureus (MIC50 16 μg/ml for methicillin-
sensitive strains and 32 μg/ml for resistant strains) and S. 
pneumoniae (MIC50 1  μl/ml for both penicillin-sensitive 
and resistant strains) by coalescing with the pyroph-
osphate moiety of lipid II, the essential precursor of the 
cell wall (Mygind et al. 2005; Schneider et al. 2010). Pep-
tide NZ2114 is a novel variant of plectasin (D9N, M13L, 
Q14R) that is significantly more potent than parental 
peptide (MIC50 2 μg/ml for S. aureus and 0.25 μg/ml for 
S. pneumoniae) (Andes et al. 2009; Ostergaard et al. 2009; 
Zhang et al. 2014). It also owned long postantibiotic effect 
(PAE) (Andes et  al. 2009) and was synergistic in combi-
nation with teicoplanin, moenomycin, and dalbavancin 
(Breidenstein et al. 2015). It had potent activities against S. 
aureus in rabbit meningitis, murine peritonitis, and thigh 
infection models (Andes et  al. 2009; Ostergaard et  al. 
2009; Xiong et  al. 2011). Additionally, NZ2114 showed 
low or no cell toxicities, long-lasting serum stability and 
in vivo half-life (Brinch et al. 2010). However, there are no 
studies focused on its activity against S. suis, the impor-
tant zoonotic pathogens. In this work, the in vitro effect of 
NZ2114 against S. suis was investigated. Furthermore, the 
in vivo pharmacodynamics characteristics were evaluated 
for future clinical development.
Materials and methods
Materials
The antimicrobial peptide NZ2114 was prepared accord-
ing to a previously described protocol (Zhang et  al. 
2014), and its purity was 94.8%. The purified, lyophilized 
NZ2114 powder was dissolved in sterilized ultrapure 
water and stored at −20 °C before subsequent antibacte-
rial assessments.
Minimal inhibitory concentration (MIC) assay
The MICs of NZ2114 were determined by the microti-
ter broth dilution method in 96 micro-well plate (Tian 
et al. 2009). The pathogens were grown to 0.4 of OD600nm 
at 37  °C in MHB medium and diluted to approximate 
1 × 105 CFU/ml with fresh MHB medium. The purified 
NZ2114 was twofold serial dilutions with gradient con-
centration of 1280, 640, 320, 160, 80, 40, 20, 10, 5, 2.5, 
1.25, and 0.625 μg/ml. A 90-μl cell suspension and 10 μl 
of serial concentration gradient solutions of NZ2114 
were added to every well. All assays were performed in 
triplicate. The ampicillin was also tested with the same 
concentration gradient as controls. Plates were incubated 
at 37  °C for 18–24  h. The MIC was defined as the low-
est concentration of ones at which there was no visible 
growth.
Bactericidal kinetics assay
The S. suis strain CVCC 606 was grown overnight in 
MH medium at 37  °C with shaking at 250  rpm. Fresh 
MH medium was inoculated with 1% (v/v) overnight 
culture and grown to mid-log phase. The 90 μl of expo-
nential-phase S. suis strain CVCC 606 (approximately 
104−5 CFU/ml) cells were incubated with 10 μl of NZ2114 
(final concentrations were 1×, 2×, and 4  ×  MIC); the 
2 × MIC ampicillin was used as control. The mixed sam-
ples were added to the wells of 96-well cell culture plates 
(each concentration sample was performed in triplicate) 
and incubated at 37  °C. The 100  μl samples from each 
well were collected after 0, 0.5, 1, 2, 3, 4, 6, 8, and 10 h 
of incubation and were serially diluted and plated on MH 
agar. Viable colonies were counted after 16–18 h at 37 °C.
Hemolytic assay
The hemolytic activity of NZ2114 was evaluated by 
determining the amount of released hemoglobin from a 
4% suspension of fresh mice red blood cells (RBCs) (Cho 
and Lee 2011). Mice RBCs were collected and washed 
with physiological saline (PS) three times. The 100  μl 
of mice RBCs diluted to 8% (v/v) in PS was seeded into 
96-well plates, and a 100  μl peptide solution was then 
added to each well (at a final concentration ranging from 
0 to 256  μg/ml). The plates were incubated at 37  °C for 
1 h and centrifuged at 1500 rpm for 10 min. Absorbance 
of the supernatants at 540  nm was measured with an 
ELISA plate reader, and 0 and 100% hemolysis was deter-
mined in PS and 0.1% Triton X-100, respectively. The 
hemolysis percentages were calculated by the following 
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equation: [(Abs540nm in NZ2114 solution  −  Abs540nm 
in PS)/(Abs540nm in 0.1% Triton X-100  −  Abs540nm in 
PS)] × 100%.
Animals
The 6-week-old female Institute for Cancer Research 
(ICR) mice, SPF, weighing 20–25  g were used for all 
in  vivo test. Mice were purchased from Wei Tonglihua 
Co., Ltd (Beijing). Animals were kept in standard Mac-
rolon cages (5–8 per cage), fed a standard pellet diet 
ad libitum, and had free access to bottled drinking water. 
Animals were acclimatized for 2–3 days prior to the ini-
tiation of the study.
Streptococcus suis infection model
Streptococcus suis CVCC606 bacteria were grown to log-
arithmic phase (OD600nm, 0.5), harvested, washed in PBS, 
diluted in the same buffer to 8.5–9.5 lg CFU/ml, and kept 
on ice until injection. Every ten mice were divided into a 
group. A 100 μl of certain concentration of bacterial sus-
pension was inoculated intraperitoneally (i.p.). The PBS 
was used as control. After injection of bacteria, survival 
rate was monitored for 7 days.
Effects of NZ2114 against S. suis in vivo
To test the protective effect of NZ2114 against S. suis 
infections in  vivo, every ten ICR female mice were 
divided into one group. Each group was inoculated i.p. 
with 1 × 108 CFU S. suis CVCC606 and various concen-
tration of NZ2114 (0.04, 0.2, 1, 2.5, 5, 10, 20, and 40 mg/
kg) were injected intravenously (i.v.) after 1 and 8 h post-
infection. The PBS and 10 mg/kg ampicillin was used as 
control. After injection of bacteria and drugs, survival 
rate was monitored for 7  days. Additionally, the blood 
and lung were collected after 24 h post-treatment; bacte-
rial loads in these tissues were calculated.
The bacterial loads in different tissues after treatment 
with NZ2114 at different time points were determined. 
ICR female mice inoculated with 1  ×  108  CFU S. suis 
CVCC606 and various concentration (10, 20, and 40 mg/
kg) of NZ2114 was injected i.v. after 1 and 8  h post-
infection. The mice were sacrificed by cervical disloca-
tion; bacterial loads in blood, lung, spleen, and liver were 
detected in 0, 2, 4, 8, and 16 h post-treatment. Every six 
mice were divided into one group and as duplicate.
Histological analysis of lung
ICR female mice were inoculated with 1 ×  108  CFU S. 
suis CVCC606 and various concentration of NZ2114 
(10, 20, and 40 mg/kg) was injected after 1 and 8 h post-
infection. The 10  mg/kg ampicillin was used as control. 
The mice were sacrificed after 24  h post-treatment and 
the lungs were removed and immediately dipped into 
4% paraformaldehyde solution in PBS for 1–3 days. The 
tissues were then embedded in paraffin, sectioned and 
4 mm sections were placed on glass slides. Slides under-
went deparaffinization and staining by hematoxylin and 
eosin.
Cytokine assay
ICR female mice were inoculated with 1 ×  108 CFU S. 
suis CVCC606 and various concentration of NZ2114 
(10, 20, and 40 mg/kg) was injected after 1 and 8 h post-
infection. The 20  mg/kg ampicillin was used as control. 
Whole blood was collected by heart puncture after 24 h 
post-treatment. The blood was incubated at 37 °C for 2 h 
and centrifuged at 3000  rpm for 5  min at 4  °C. Serum 
was collected from supernatant. The cytokines of TNF-α, 




The NZ2114 displayed potent antimicrobial activ-
ity against Gram-positive bacteria such as S. suis, S. 
aureus and S. pneumonia, especially for S. suis (MIC 
0.03–0.06  μM) (Table  1). The MBCs ranged from 0.06 
to 0.12  μM. The activity of NZ2114 to S. aureus and S. 
pneumonia was lower than that to S. suis, with the MICs 
ranged from 0.03 to 0.9  μM to S. aureus ATCC25923, 
6538 and 43300 and 1.8–3.6  μM to S. pneumonia 
CMCC31968 and 2350, respectively (Table  1). In addi-
tion, the activity of NZ2114 against S. suis was stronger 
compared to ampicillin (MIC 0.17–0.34 μM) (Table 1).
Time‑killing curves of NZ2114
Time-killing curves were generated to demonstrate the 
bactericidal ability of NZ2114 against S. suis CVCC606. 
As shown in Fig. 1a, in the absence of NZ2114, the bacte-
rial counts (lg CFU/ml) reached to 8.92 at 10 h. It exerted 
a dose-related pattern of inhibition for S. suis CVCC606. 
A decrease in S. suis CVCC606 of 1.28 and 1.83 lg CFU/
ml (>90% reduction) was observed within 3 h at one and 
two times of MIC, respectively. Those decreases were 
nearly equal to that obtained by ampicillin treatment 
(1.49 lg CFU/ml decrease) at two times of MIC (Fig. 1a), 
but NZ2114 failed to inhibit bacterial regrowth after 3 
and 4  h of inoculate for 1× and 2 ×  MIC, respectively. 
However, a huge and stable decrease was found within 
10 h at 4 × MIC (lg CFU/ml from 5.13 to 2.64, bacteri-
cidal efficiency >99%).
Hemolytic assay
The cytotoxicity of NZ2114 was tested by measuring its 
ability to lyse mice RBCs. There was no obvious hemoly-
sis of RBCs within 64 μg/ml and the hemolytic activities 
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at concentrations of 128 and 256  μg/ml  were 0.153, 
0.241%, respectively (Fig.  1b). It is critical that NZ2114 
displays little or no hemolytic activity for its application 
in internal medicine.
Absolute lethal dose assay
As shown in Fig. 2, all mice were alive when i.p. injected 
with PBS after 7 days. The survival rate of mice injected 
with 8.5 and 8.75  lg  CFU/ml S. suis CVCC606 were 80 
and 60%, respectively. All mice were died at 7 days after 
injected with 9, 9.25, and 9.5 lg CFU/ml S. suis CVCC606. 
However, the mice injected with 9.5  lg CFU/ml bacteria 
were died immediately within only 1  day, and the mice 
injected with 9 and 9.25 lg CFU/ml bacteria were died at 
3  days postinjection. To evaluate the therapeutic effects 
in a continuous way, the inoculum concentration of 
9 lg CFU/ml was chosen to further research.
Dosage effect of NZ2114
It was shown that NZ2114 improved survival for all 
treatment groups (Fig.  3a). All mice injected with 0.2–
40  mg/kg NZ2114 were alive except that of 0.04  mg/kg 
Table 1 MIC and MBC assays of NZ2114 and ampicillin to S. suis, S. aureus, S. pneumonia, and E. coil
NT no tested
a China Institute of Veterinary Drug Control
b China General Microbiological Culture Collection Center
Strains Source MIC (μM) MBC (μM)
NZ2114 Ampicillin NZ2114 Ampicillin
S. suis CVCC606 CVCCa 0.03 0.17 0.03 0.34
S. suis CVCC3309 CVCC 0.03 0.34 0.06 0.34
S. suis CVCC3928 CVCC 0.06 0.34 0.06 1.02
S. aureus ATCC25923 CVCC 0.03 1.35 0.06 1.35
S. aureus ATCC6538 CGMCCb 0.11 1.35 0.11 2.69
S. aureus ATCC43300 CGMCC 0.9 10.78 0.9 21.56
Streptococcus pneumoniae CGMCC1.8722 CGMCC 0.45 1.35 0.9 2.69
S. pneumoniae CVCC2350 CVCC 0.9 2.69 1.8 5.38
S. pneumoniae CVCC31968 CVCC 0.9 2.69 0.9 2.69
E.coli CVCC195 CVCC ≥29.09 0.31 ≥29.09 0.31
E.coli CVCC1515 CVCC ≥29.09 NT ≥29.09 NT
Fig. 1 Time-killing curves and hemolytic assay of NZ2114. a Time-killing curves of NZ2114 against S. suis CVCC606. S. suis CVCC606 were incubated 
in the presence of medium alone (CK), in the presence of NZ2114 at 1×, 2×, and 4× MIC, or in the presence of ampicillin at 2 × MIC, three dupli-
cate observations were made; bars represent the standard error of the mean. b Hemolytic assay of NZ2114. The 4% erythrocytes were incubated 
with different concentration of NZ2114, the 0.9% NaCl and 0.1% Triton X-100 were used as negative and positive controls. Three duplicate observa-
tions were made; bars represent the standard error of the mean
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(Fig.  3a). No obvious colony was observed in the blood 
of mice injected with 5–40 mg/kg NZ2114. However, the 
lg CFU/ml of S. suis CVCC606 increased significantly 
from 0.74 to 6.50 with the NZ2114 concentration of 2.5, 
1, 0.2 and 0.04  mg/kg, respectively (Fig.  3b). In addi-
tion, NZ2114 with the concentration of 10, 20, 40  mg/
kg could effectively kill the pathogens and no colony was 
observed in lung after 24 h of injection. The lg CFU/ml 
of S. suis CVCC606 was 2.01 and 2.04 with the dosage of 
5 and 2.5 mg/kg and it increased from 3.23 to 5.64 with 
the reduction of injection dose (1, 0.2, and 0.04  mg/kg) 
(Fig. 3c).
Effects of NZ2114 against S. suis on various organs
The bacterial loads in different organs were monitored 
at 2, 4, 8, 16, and 24 h postinfection after treatment with 
NZ2114 and control ampicillin. S. suis was distributed at 
high concentrations in different organs and blood at 4 h 
(8.97–11.87 lg CFU/ml) and 8 h (9.92–12.06 lg CFU/ml) 
postinfection. Meanwhile, the bacterial loads in blood 
showed sharp decrease and hardly detected at 16 h post-
treatment with 10, 20, and 40 mg/kg NZ2114. The ampi-
cillins with 10 mg/kg led to 5.313 lg CFU/ml reduction in 
24 h postinfection (Fig. 4a).
The bacterial loads in lung, spleen, and liver showed 
obvious dose-dependent effect (Fig.  4b–d). There was 
significant reduction of the CFU counts in lung, with 
the most rapid decrease being observed in 4  h post-
treatment, the bacterial loads were 2.560, 2.903, and 
3.995  lg  CFU/0.1  g with 40, 20 and 10  mg/kg NZ2114, 
respectively. However, the bacterial loads remained 
stable until the retreatment in 8  h and no colony were 
detected in 24 h posttreatment (Fig. 4b). Similarly, there 
was significant reduction of the CFU counts in 4 h post-
treatment, showing lg colony counts of 2.512, 4.345, 
4.689 in spleen and 3.078, 4.313, 4.506 in liver for 40, 20, 
and 10 mg/kg NZ2114, respectively (Fig. 4c, d). Moreo-
ver, there was no colony in 24 h at all NZ2114 treatment 
groups.
Effects of NZ2114 against S. suis infection in lung 
histopathology
There was no histological sign of infection and inflam-
mation in the lung tissue of uninfected group (Fig. 5a). In 
contrast, the histology of untreated mice showed severe 
inflammatory reactions such as infiltration of inflam-
matory cells, alveolar collapse, alveolar hemorrhage 
and bronchioli terminals epithelium damage (Fig.  5b). 
NZ2114 could reduce the lesions of lung tissues in a dose 
dependent manner (Fig.  5c–e). There was no obvious 
inflammation in the 20 and 40 mg/kg NZ2114 treatment 
group, which was recovered almost the same as unin-
fected group (Fig. 5d, e).
Effects of NZ2114 in the cytokine levels
To expose the anti-inflammatory effect of NZ2114 on 
mice, the levels of inflammatory cytokines TNF-α, IL-6 
and IL-10 were analyzed after 24  h post-treatment. 
As shown in Fig.  6, there were low cytokine levels in 
the uninfected group (13.798  pg/ml for TNF-α and 
16.256 pg/ml for IL-6). The S. suis infection could signifi-
cantly increase cytokine levels to 248.19 and 1458.60 pg/
ml, respectively (Fig.  6a, b). Conversely, treatment with 
NZ2114 efficiently reduced the production of TNF-α and 
IL-6, reducing to the normal levels (15.679–19.671 pg/ml 
for TNF-α and 52.666–149.813 pg/ml for IL-6) (Fig. 6a, 
b). In contrast, no obvious changes of expression of IL-10 
were exhibited in control and treatment groups (data not 
shown).
Discussion
Antimicrobial peptides (AMPs) have attracted much 
attention in recent years for their potent activity against 
a variety of pathogens, including drug-resistant bacteria. 
Currently, 2718 types of AMPs are registered in the anti-
microbial peptide database (APD) (http://aps.unmc.edu/
AP/main.php). However, only a few of them advanced 
into clinical trials due to several bottlenecks, includ-
ing poor antimicrobial activity, low stability, high toxic-
ity and lack of efficient approaches to commercial-scale 
production (Eckert 2011; Yeung et al. 2011; Zasloff 2002). 
NZ2114 was a novel plectasin mutant identified through 
a high-throughput mutation, which had improved 
potency against S. aureus and S. pneumoniae (Andes 
et  al. 2009; Ostergaard et  al. 2009) and high expression 
yield (2.39  g/l in the supernatant of Pichia pastoris) 
Fig. 2 Absolute lethal dose assays. Every ten mice were divided into 
a group. Each group was injected with a certain concentration of S. 
suis CVCC606 (100 μl of 8.5–9.5 lg CFU/ml). The PBS was used as con-
trol. After injection of bacteria, survival rate was monitored for 7 days
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(Zhang et  al. 2014). Our previous studies showed that, 
plectasin and its derived peptide MP1106 were very 
active against G+ pathogens, such as S. suis, S. aureus and 
S. pneumonia, especially for S. suis (MIC 0.03–0.06 μM) 
(Cao et  al. 2014; Jiao et  al. 2015; Zhang et  al. 2011). 
However, there was no detailed research on the in vitro 
and vivo characteristic of NZ2114 against S. suis—the 
pathogen of zoonosis got great public attentions in recent 
years. In this work, NZ2114 had the best activity against 
S. suis (MIC 0.03–0.06 μM) (Table 1). In addition, it could 
Fig. 3 Dosage effect of NZ2114. a Effects of NZ2114 on the survival rate of mice. Every ten ICR female mice were divided into one group. Each 
group was inoculated with 1 × 108 CFU S. suis CVCC606 and various concentration of NZ2114 was injected after 1 and 8 h post-infection. The PBS 
was used as control. After injection of bacteria, survival rate was monitored for 7 days; b Effects of NZ2114 on the bacterial loads in blood after 24 h 
post-treatment. Every six mice were divided into a group and as duplicate, bars represent the standard error of the mean; c Effects of NZ2114 on the 
bacterial loads in lung after 24 h post-treatment. Every six mice were divided into a group and as duplicate, bars represent the standard error of the 
mean
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kill 99% pathogens within 4 h at 2 and 4 × MICs (0.06–
0.12 μM), having no bacterial regrowth after 4 h of inocu-
late (Fig. 1a). The MP1106 also significantly inhibited the 
growth of pathogen but was in high concentration (0.24 
and 0.48  μM for 4 and 8  ×  MICs), there was no obvi-
ous bacterial regrowth only in the 8 and 16 × MICs (Jiao 
et  al. 2015). The more excellent anti-S. suis characteris-
tic makes it as a potential antimicrobial drug for S. suis 
infection treatment.
The hemolysis was often evaluated for candidate AMPs 
as a new agent through intravenous injection (Park et al. 
2006; Tian et al. 2009). NZ2114 and plectasin have been 
proven to have no hemolysis to human erythrocytes (less 
than 0.1% in 128  μg/ml) and no toxicity to A549 cells, 
normal human bronchial epithelial cells, or lung fibro-
blasts in 50 μg/ml (Hara et al. 2008; Mygind et al. 2005; 
Zhang et  al. 2014). As expected, NZ2114 also showed 
a very low hemolytic activity (<0.3%) against mouse 
erythrocytes even in the high concentration of 256  μg/
ml (Fig. 1b). The low toxicity to both model animal and 
human erythrocytes make it convenient for intravenous 
injection for further research and clinical use.
The plectasin and NZ2114 had potent activity in differ-
ent animal infection models. The in vivo efficacy of plec-
tasin (10 mg/kg) was comparable to vancomycin (70 mg/
kg) in the peritoneal model and to penicillin (30 mg/kg) 
in pneumonia model caused by S. pneumoniae (Mygind 
et  al. 2005). It was shown that NZ2114 (10, 40 and 
160 mg/kg) could effectively killed S. aureus and S. pneu-
moniae in neutropenic murine thigh infection model. 
The counts of pathogen decreased over 99% within 
5  h. There was regrowth with 10  mg/kg NZ2114 in S. 
Fig. 4 Effects of NZ2114 on bacterial loads of S. suis in various organs. ICR female mice was inoculated with 1 × 108 CFU S. suis CVCC606 and vari-
ous concentration (10, 20, and 40 mg/kg) of NZ2114 was injected after 1 and 8 h post-infection. The bacterial loads in blood (a), lung (b), spleen (c), 
and liver (d) were detected in 0, 2, 4, 8, and 16 h post-treatment. Every six mice were divided into one group and as duplicate, bars represent the 
standard error of the mean
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pneumoniae group and all dosage in S. aureus group after 
5 h of therapy (Andes et al. 2009). Additionally, there was 
a significantly higher level of cerebrospinal fluid (CSF) 
penetration of NZ2114 through inflamed than through 
non inflamed meninges. Treatment with NZ2114 (40 
and 20 mg/kg), caused a significantly higher reduction in 
CSF bacterial concentrations than therapy with ceftriax-
one (125 mg/kg) at 3, 5 and 10 h (Ostergaard et al. 2009). 
In this work, NZ2114 showed strong activity to S. suis. 













Fig. 5 Lung histopathology from different NZ2114 concentration experimental groups. ICR female mice were inoculated with 1 × 108 CFU S. 
suis CVCC606 and various concentration of NZ2114 (10, 20, and 40 mg/kg) was injected after 1 and 8 h post-infection. The mice were sacrificed 
after 24 h post-treatment and lung tissue was collected for histological evaluation. a Control group; b S. suis CVCC606 infection group; c S. suis 
CVCC606 + 10 mg/kg NZ2114; d S. suis CVCC606 + 20 mg/kg NZ2114; e S. suis CVCC606 + 40 mg/kg NZ2114; f S. suis CVCC606 + 20 mg/kg ampi-
cillin. A alveoli, T bronchioli terminals, V vessel, 1 infiltration of inflammatory cells, 2 alveolar collapse, 3 alveolar hemorrhage, 4 bronchioli terminals 
epithelium damage
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and there was no pathogen in blood (5 mg/kg) and lung 
(10  mg/kg) (Fig.  3b, c). S. suis loads of organs further 
revealed that there were no pathogen existed in blood, 
lung, liver and spleen after 24 h of treatment (twice injec-
tion, 1 and 8 h of postinfection) in all dosages (10, 20 and 
40  mg/kg) (Fig.  4). Other antimicrobial agents had the 
same effects but in high dosage. The 80 mg/kg (calculated 
at 25 g per rat) Ply30 (the bacteriophage lysin) protected 
80% (8/10 mice) of mice from infection with S. suis. Seven 
days after lysin Ply30 treatment, bacterial loads were sig-
nificantly decreased in all tested organs and blood com-
pared with control group (Tang et al. 2015). It was shown 
that 8.6 and 28.02 mg/kg of cefquinome was required for 
1-lg killing of S. suis ATCC 43765 with the initial inocu-
lum of 108 and 106 CFU, respectively (Guo et  al. 2016). 
The low injection dosage and high efficiency of NZ2114 
in the mice model indicates that the drug resistance will 
be rare and it is suitable for the clinical treatment of S. 
suis infection.
Pulmonary injury could be the direct cause of S. suis 
-induced animal death (Lun et al. 2007). Lung inflamma-
tion is characterized by increased pulmonary inflamma-
tory cell sequestration, which leads to the development 
of protein leakage in alveolar space, reduced lung compli-
ance, and finally impaired lung function (Chu et al. 2010). 
It was shown that NZ2114 could reduce the lesions of 
lung tissues such as alveolar collapse and alveolar hem-
orrhage in a dose dependent manner, indicating that it is 
also conducive to the recovery of pulmonary injury.
TNF-α is the first endogenous cytokine released from 
monocytes and macrophages, which induces the inflam-
matory cascade and aggravates injuries (Malleo et  al. 
2007). Additionally, it leads to apoptosis by activating the 
caspases enzyme system in endothelial cells which com-
promises the integrity of the vascular barrier (Goldblum 
and Sun 1990). IL-6 is also a vital cytokine with strong 
influences on inflammatory responses and a crucial 
indicator (Strandberg et al. 2005). IL-10 has emerged as 
a key immunoregulator during infection. It can directly 
regulate innate and adaptive Th1 and Th2 responses by 
limiting T cell activation and differentiation in the lymph 
nodes as well as suppressing proinflammatory responses 
in tissues, leading to impaired pathogen control and/or 
reduced immunopathology (Couper et  al. 2008). In this 
work, NZ2114 clearly reduced the levels of TNF-α, and 
IL-6 compared to the infection group (Fig. 6). These find-
ings suggest that the protective effect of NZ2114 is partly 
attributed to inhibit the levels of pro-inflammatory 
cytokines. However, the level of anti-inflammatory IL-10 
was ruleless (data not shown). Considering that IL-10 is 
pleiotropic functions, further studies are necessary to 
evaluate the immune state.
Fig. 6 Effects of NZ2114 on the pro-inflammatory cytokines of TNF-α and IL-6 in serum. ICR female mice were inoculated with 1 × 108 CFU S. suis 
CVCC606 and various concentration of NZ2114 (10, 20, and 40 mg/kg) was injected after 1 h post-infection. The mice were sacrificed after 24 h 
post-treatment and serum was collected for cytokines of TNF-α (a) and IL-6 (b) analysis. Three duplicate observations were made; bars represent the 
standard error of the mean
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In conclusion, NZ2114 showed strong antimicrobial 
activity against Gram-positive bacteria, especially to S. 
suis. It had very low hemolysis to mice RBCs in safe appli-
cation concentrations. It was also found that NZ2114 had 
potent in  vivo activity to S. suis. All mice were survival 
when the dosage was low to 0.2 mg/kg and no pathogens 
were detected in blood, lung, liver and spleen with dos-
age of 10, 20 and 40 mg/kg after 24 h of treatment. Fur-
ther, no pathological phenomenon in lung and low level 
of inflammatory cytokines in blood were detected. Above 
all, the in vitro and in vivo bactericidal profiles of NZ2114 
indicating it is an ideal candidate for a new antimicrobial 
agent against S. suis infection.
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